This study examines the 2023 NCCN Guidelines Insights for metastatic breast cancer, highlighting updates in systemic therapy recommendations. Tumor biology and clinical factors are integrated to inform treatment decisions for stage IV breast cancer. The guidelines emphasize the importance of considering hormone receptor status, HER2 expression, and molecular profiling in determining optimal therapeutic strategies, thereby enhancing personalized medicine approaches for patients with advanced breast cancer.